Opus Genetics, Inc. Operating Lease, Payments
Opus Genetics, Inc. (IRD) reported Operating Lease, Payments of $116.06 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2020-10-29
- Opus Genetics, Inc. operating lease, payments for the quarter ending 2020-09-30 was $39.22K, a 2.50% increase year-over-year.
- Opus Genetics, Inc. operating lease, payments for the quarter ending 2020-06-30 was $38.58K, a 7.02% increase year-over-year.
- Opus Genetics, Inc. operating lease, payments for the quarter ending 2020-03-31 was $38.26K, a 54.80% decline year-over-year.
- Opus Genetics, Inc. operating lease, payments for the quarter ending 2019-12-31 was $38.26K.
- Opus Genetics, Inc. operating lease, payments for fiscal 2019 was $197.22K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2020-09-30 | $39.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $77.80K derived: sum of 2 quarters · filed 2020-10-29 | $116.06K 10-Q · filed 2020-10-29 | $154.32K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $38.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $76.84K 10-Q · filed 2020-08-14 | $115.11K derived: sum of 3 quarters · filed 2020-08-14 | $153.37K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $38.26K 10-Q · filed 2020-05-07 | $76.52K derived: sum of 2 quarters · filed 2020-05-07 | $114.79K derived: sum of 3 quarters · filed 2020-10-29 | $150.84K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $38.26K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $76.52K derived: sum of 2 quarters · filed 2020-10-29 | $112.57K derived: sum of 3 quarters · filed 2020-10-29 | $197.22K 10-K · filed 2020-02-21 |
| 2019-09-30 | $38.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $74.31K derived: sum of 2 quarters · filed 2020-10-29 | $158.96K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $36.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $120.70K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $84.65K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |